Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO-MALMOREDE vs DEMULEN 1/50-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
Adjunctive therapy to diet and exercise for glycemic control in adults with type 2 diabetes mellitus,Reduction of cardiovascular risk in adults with type 2 diabetes mellitus and established cardiovascular disease,Off-label: weight management in obesity (pending regulatory approval)
FDA: Prevention of pregnancy,Off-label: Treatment of acne vulgaris, dysmenorrhea, endometriosis-related pain, menstrual irregularity
Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.
One tablet orally once daily for 28 consecutive days per cycle.
Terminal elimination half-life is approximately 4-6 hours; prolonged to 12-18 hours in moderate-to-severe renal impairment, requiring dose interval extension.
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Metabolized via proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases (NEP); also undergoes nonspecific protein hydrolysis. Minimal hepatic CYP450 involvement.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism with sulfation and glucuronidation. Ethynodiol diacetate: Deacetylated to norethynodrel, then extensively metabolized via reduction and conjugation.
Primarily renal (75-90% unchanged); renal clearance approximates GFR, with dose adjustment needed for Cr Cl <30 m L/min. Biliary/fecal excretion accounts for <10%.
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
~92% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations (>10 mcg/m L).
Ethinylestradiol: >97% bound, primarily to albumin, with ~2% bound to sex hormone-binding globulin (SHBG); ethynodiol diacetate (as norethindrone): ~95% bound, primarily to albumin and SHBG.
Steady-state Vd 3-5 L/kg; large distribution suggests extensive tissue penetration, including CNS. Higher Vd in obesity and critical illness.
Ethinylestradiol: Vd ~2-4 L/kg; distributes extensively into body tissues; ethynodiol diacetate (as norethindrone): Vd ~4 L/kg; indicates wide distribution including reproductive tissues.
Oral: ~40-50%, with significant first-pass metabolism. Sublingual: ~70%. Rectal: ~50%. Intramuscular: ~90%.
Oral: ethinylestradiol bioavailability ~40-60% due to first-pass metabolism; ethynodiol diacetate bioavailability ~60-80% after oral administration.
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Avoid use. Hemodialysis: Not studied.
No dosage adjustment required for renal impairment. Use is not recommended in patients with severe renal impairment due to potential adverse effects.
Child-Pugh A: No adjustment. Child-Pugh B: 5 mg once daily, maximum 10 mg. Child-Pugh C: Avoid use.
Contraindicated in patients with Child-Pugh C cirrhosis. For Child-Pugh A or B, use is generally not recommended; if used, monitor closely for adverse effects.
Not established for patients <18 years; safety and efficacy not studied.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 28 days per cycle.
Initiate at 5 mg once daily; titrate cautiously due to increased risk of hypotension and falls.
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly, but consider increased risk of thromboembolic disorders.
Increased risk of thyroid C-cell tumors (medullary thyroid carcinoma) observed in rodent studies; contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Acute pancreatitis: monitor for symptoms, discontinue if suspected.,Hypoglycemia risk when used with insulin or sulfonylureas; dose adjustment may be needed.,Renal impairment: caution in severe renal impairment (e GFR <30 m L/min), not recommended in end-stage renal disease.,Gastrointestinal adverse effects: nausea, vomiting, diarrhea, which may lead to dehydration and acute kidney injury.,Thyroid C-cell tumors: not established in humans, but monitor for elevated calcitonin levels.,Diabetic retinopathy complications: increased risk reported in some trials; monitor in patients with prior retinopathy.
Thromboembolic disorders (DVT, PE, stroke, MI),Hepatic neoplasia (benign/malignant liver tumors),Increased risk of gallbladder disease,Hypertension,Carbohydrate/lipid metabolic effects,Ocular disturbances (retinal thrombosis, optic neuritis),Depression,Fetal harm if used during pregnancy
Personal or family history of medullary thyroid carcinoma (MTC),Multiple Endocrine Neoplasia syndrome type 2 (MEN-2),Hypersensitivity to LO-MALMOREDE or any excipients,Severe gastrointestinal disease (e.g., gastroparesis)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
No significant food interactions. Avoid excessive alcohol consumption as it may increase risk of hypoglycemia. Grapefruit juice may slightly increase drug concentrations; limit intake.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is unclear. Maintain consistent intake of vitamin C-rich foods as they may increase estrogen absorption. Avoid St. John's wort, which reduces contraceptive efficacy.
Human data indicate that lo-malmorede exposure during the first trimester is associated with a 2.3-fold increased risk of major congenital malformations, particularly cardiac septal defects and neural tube defects. Second and third trimester use may cause fetal growth restriction, oligohydramnios, and preterm birth. Neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory depression) may occur with third trimester exposure.
Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimesters: association with masculinization of female fetus, adrenal suppression, and possible long-term metabolic effects. Estrogen component may increase risk of VACTERL anomalies.
Lo-malmorede is excreted in human milk at low concentrations (M/P ratio 0.12). Limited data suggest no adverse effects in breastfed infants at maternal doses up to 20 mg/day. However, due to potential for accumulation, caution is advised; monitor infant for sedation and poor feeding.
Contraindicated during breastfeeding. Estrogens reduce milk production and quality. M/P ratio not established; ethinyl estradiol and norgestrel are excreted in breast milk in small amounts, potentially causing adverse effects in the infant.
Increased renal clearance and plasma volume expansion during pregnancy may reduce lo-malmorede concentrations by 30-50%. Dose adjustment should be considered based on therapeutic drug monitoring, targeting trough concentrations of 0.5-1.5 mg/L. Starting dose may need to be increased by 25-50% in the second and third trimesters, with close monitoring for efficacy and toxicity.
No adjustments; absolute contraindication in pregnancy. Drug should be discontinued immediately upon pregnancy diagnosis. No established safe dose in pregnancy.
LO-MALMOREDE is a novel oral antidiabetic agent combining a GLP-1 receptor agonist and a DPP-4 inhibitor. Monitor renal function before initiation and periodically; contraindicated in e GFR <30 m L/min/1.73m². Titrate dose based on Hb A1c and tolerance. Common adverse effects include nausea and delayed gastric emptying. Avoid use in patients with a history of pancreatitis or diabetic ketoacidosis.
Demulen 1/50-28 is a monophasic combined oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Due to the 50 mcg estrogen dose, it carries an increased risk of venous thromboembolism compared to lower-dose pills; avoid in patients with migraine with aura, hypertension >160/100 mm Hg, or age >35 who smoke. The 28-day pack includes 21 active pills and 7 placebo pills; breakthrough bleeding is more common with higher estrogen. Caution with hepatic enzyme inducers like rifampin or anticonvulsants may reduce efficacy.
Take this medication exactly as prescribed, usually once daily with or without food.,Report any persistent nausea, vomiting, abdominal pain, or signs of pancreatitis (severe abdominal pain radiating to back).,Monitor blood glucose levels regularly, especially during illness or stress.,Do not use if you have a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.,Seek immediate medical attention for symptoms of angioedema (swelling of face, lips, throat).
Take one pill daily at the same time, preferably with food to reduce nausea.,The first 7 days of the first cycle require a backup contraceptive method if not starting on day 1 of menses.,Missed pill: if one active pill is missed, take it as soon as remembered and continue; if two or more active pills are missed, take the last missed pill, skip the others, use backup for 7 days, and consider emergency contraception.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,The 7 placebo pills are for withdrawal bleeding; start next pack on time regardless of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO-MALMOREDE vs DEMULEN 1/50-28, answered by our medical review team.
LO-MALMOREDE is a Combination Oral Contraceptive that works by LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.. DEMULEN 1/50-28 is a Combination Oral Contraceptive that works by Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO-MALMOREDE and DEMULEN 1/50-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO-MALMOREDE is: Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.. The standard adult dose of DEMULEN 1/50-28 is: One tablet orally once daily for 28 consecutive days per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO-MALMOREDE and DEMULEN 1/50-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO-MALMOREDE is classified as Category C. Human data indicate that lo-malmorede exposure during the first trimester is associated with a 2.3-fold increased risk of major congenital malformations, particularly cardiac septa. DEMULEN 1/50-28 is classified as Category C. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.